|
시장보고서
The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery
|
Abstract
Biobanks collect and store human biospecimens, playing a vital role in the
development of novel drugs and diagnostics. In recent years, large
population-based biobanks have been established which monitor the health
status of participants over time to assess the natural occurrence and
progression of common diseases. Hundreds of disease-based biobanks are located
around the world, which are a valuable resource for biomarker discovery as
well as for studying progression, mortality and responses to treatment. - The
Future of Biobanks - is a new report published by Business Insights that
examines major trends in the biobanking industry and identifies the key
initiatives to upgrade the biobanking infrastructure. This report explores the
applications of biobanks and provides examples of how large sets of
high-quality biosamples are creating new ways to diagnose, prevent and treat
diseases. The activities of over 180 US biobanks are assessed to illustrate
how the scale and scope of biobanking is changing. This report also evaluates
the limitations of biobanks, in addition to reviewing the unique legal,
regulatory and ethical issues that surround this new frontier of biomolecular
research.
Table of Contents
The Future of Biobanks Executive summary Overview Biobanking trends
Population-based biobanks Disease-based biobanks Private-sector biobanks
Regulatory and ethical issues
Chapter 1 Overview
- Summary
- Introduction
- Definition of biobanks
- Historical context
- Scientific and commercial relevance of biobanks
- Targeted therapeutics
- Diagnostic and prognostic tests
- Drug development
- Disease etiology
- Future outlook
Chapter 2 Trends in biobanking
- Introduction
- Introduction
- The limitations of biobanks
- Initiatives to improve biobanks
- Sample variability
- Sample quality
- Older biobanks
- Modern biobanks
- Biobanking costs
- Increasing harmonization
- Future outlook
Chapter 3 Population-based biobanks
- Introduction
- Introduction
- Types of population biobanks
- Cohort studies
- Founder population biobanks
- deCODE Genetics
- CARTaGENE
- Genizon Biosciences
- Jurilab
- National population biobanks
- UK Biobank
- LifeGene
- Estonian biobank
- Latvian biobank
- Canadian Partnership for Tomorrow Project
- Other national biobanks
- Future outlook
Chapter 4 Disease-based biobanks
- Introduction
- Introduction
- Growth in disease-based biobanks
- Cancer biobanks
- Other diseases
- Healthy sample biobanks
- Collaborative networks
- onCORE UK
- International Genomics Consortium
- Cancer Genome Atlas
- Future outlook
Chapter 5 Private-sector biobanks
- Introduction
- Introduction
- Licensed biobanks in the UK
- Contract service providers
- Biomarker discovery companies
- Pharmaceutical collections
- Research collaborations
- Clinical trials
- Future outlook
Chapter 6 Regulatory and ethical issues
- Summary
- Introduction
- Current regulatory framework
- Informed consent
- Withdrawal and ownership
- Confidentiality
- Commercialization
- Future outlook
Appendix
List of Figures
- Figure 1.1: Cumulative number of DNA samples banked in population-based
studies*, 1970-2009
- Figure 1.2: NIH sponsored clinical trials conducting gene expression
profiling, 2000-08
- Figure 2.1: Geographical distribution of biobanks
- Figure 2.2: Drivers and resistors
- Figure 2.3: The evolution of biobanks
- Figure 4.1: Number of diseases-based biobanks, by therapy area, US
1995-2008
- Figure 5.1: Establishments licensed to operate biobanks, by sector,
England, Wales and Northern Ireland, 2008
- Figure 5.2: Examples of private-sector biobanks
List of Tables
- Table 1.1: Applications of biobanks
- Table 2.1: Types of biobanks
- Table 3.1: Selected population-based cohort studies
- Table 3.2: Population-based biobanks
- Table 4.1: Selected cancer biobanks, US
|
